

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



韋俊 生物 科技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

APPOINTMENT OF COMPANY SECRETARY

Reference is made to the announcement of Wai Chun Bio-Technology Limited (the “**Company**”) dated 21 May 2024 in relation to, among other things, the resignation of Mr. Lam Kai Kei, as a company secretary (the “**Company Secretary**”) and an authorised representative (the “**Authorised Representative**”) of the Company under Rule 3.28 and 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) respectively.

The board (the “**Board**”) of the directors (the “**Directors**”) of the Company is pleased to announce that Mr. Fenn David (“**Mr. Fenn**”) as the Company Secretary under Rule 3.28 of Listing Rules, with effect from 1 June 2024.

Mr. Fenn, aged 43, he obtained his bachelor of laws degree with honours from The University of Hong Kong in December 2002. He was awarded the postgraduate certificate in laws by The University of Hong Kong in June 2003. Mr. Fenn further obtained a master of laws degree in banking and finance from University College London, University of London in the United Kingdom in November 2006. Mr. Fenn was admitted as a solicitor in Hong Kong in September 2005 and is specialised in the field of securities compliance, disputes resolution, winding-up and restructuring. He was appointed as an adjudicator of the Registration of Persons Tribunal of Hong Kong from November 2013 to October 2019. He has been appointed as a disciplinary panel member of the Hong Kong Institute of Certified Public Accountants from February 2016 to January 2023, a member of the Appeal Panel (Housing) of the Transport and Housing Bureau of Hong Kong from April 2017 to March 2021. He was the independent non-executive director of Bradaverse Education (Int’l) Investments Group Limited (Formerly known as Hong Kong Education (Int’l) Investments Limited) (stock code: 1082) from May 2018 to January 2023. He is currently an independent non-executive director of Stream Ideas Group Limited (stock code: 8401) and Sun Kong Holdings Limited (stock code: 8631), the shares of which are listed on GEM of the Stock Exchange. He was a company secretary and authorised representative of Wai Chun Group Holdings Limited (stock code: 1013) and Wai Chun Bio-Technology Limited (stock code: 0660), the shares of which are listed on Main Board of the Stock Exchange from February 2022 to July 2023.

Mr. Fenn meets the qualifications of company secretary as required under Rule 3.28 of the Listing Rules.

Upon the appointment of Mr. Fenn as a Company Secretary becoming effective on 1 June 2024, the Company has re-complied with the requirement under Rule 3.28 of the Listing Rules.

The Board would like to extend a warm welcome to Mr. Fenn on his new appointment.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Executive Director

Hong Kong, 1 June 2024

As at the date of this announcement, the executive Director, namely Mr. Lam Ka Chun and independent non-executive Directors, namely Mr. Wan Bo and Mr. HE Tao.